Drug firm Cadila Healthcare on Friday said the US health regulator issued no observations after the inspection of its Dabhasa facility in Gujarat.
The US Food and Drug Administration (USFDA) inspected company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from October 7 to October 11, 2019, Cadila Healthcare said in a statement.
Dabhasa facility is the company's largest API manufacturing site, it added.
"This was a current good manufacturing practice (cGMP) audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) is issued," Cadila Healthcare said.
Shares of Cadila Healthcare closed at Rs 230.10 on the BSE, down 0.86 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app